Breaking Innovation Paralysis

Dan Wasserman is the founder and CEO of Mammoth Health Innovation and the creator of CHIEFS (Customers, Health Economics, Impact, Execution, Financials and Scalability), a tool that benchmarks a Canadian health innovation against an American one at the same stage of development, then lays out the actions needed to level the playing field. Over a 40-year career, with the past 28 years split between Canada and the United States, Dan has worked in competitive intelligence, IP insights and business development for IBM, AT&T, Hollywood studios, airlines and banks. He also spent a decade in Washington, DC, including lobbying on Capitol Hill. He mentored early-stage companies at ventureLAB, where he created the Health Ecosphere program before spinning out Mammoth, and he is an adjunct professor in the innovation stream at the Icahn School of Medicine at Mount Sinai. Dan holds a biology degree from the University of Toronto and an MBA from the Schulich School of Business, and he is a published novelist.

Dan opens with a story about commercial creativity. In the mid-1990s, Sympatico, the phone companies’ new internet service, was falling far short of its sign-up target. Dan struck a deal with Christie to put instant-win Sympatico offers inside Oreo packages across the country. The launch finished the year with 140,000 sign-ups against a goal of 100,000, and “the only thing Christie insisted we pay for was the $300 in colour separations.”

From there, he compares how the two countries think about commercialization. In the US, SBIR and STTR funding expects a commercialization plan, and investors ask founders how they deployed that money and whether they have pre-sales. In Canada, he sees strong support for research and far less for getting products to market. He describes the Health Ecosphere he built at ventureLAB, which brought together finance, legal, IP, government and hospital partners after health system leaders said they welcomed innovation and the companies in the room said they couldn’t get through the door. The work later received FedDev funding, and Dan sees its legacy in CAN Health Network and OBIO’s Early Adopter Health Network.

Dan then walks through how CHIEFS came to be. He started from 50 criteria that separate American successes from Canadian ones, distilled them into 10 factors, and organized them into six pillars. A factors report shows innovators where they need to pull their socks up, and a pillars profile tells investors whether a company is worth considering. Execution is where companies fall down most often, he says, and the smartest scientific founders bring in business people early, because “100% of zero is still zero.”

The conversation closes on what it takes to keep companies in Canada. Dan makes the case for exits to Canadian buyers backed by Canadian pension capital, and traces part of the problem to the 1990s Bank Act changes. He explains what Canada should copy from the holding-period rules in the US QSBS program, and why US funders back several competitors at once so that failure isn’t a penalty. He also talks about Canada’s shortage of commercialization talent, what Estonia’s integrated digital systems show is possible, and why drugs designed by AI still have to prove themselves in human trials.

Dan’s message is that Canada already pays for the science, and the next step is building commercialization into how we fund, buy and keep our innovations.

If this shifted how you think about Canada’s innovation gap, share it with someone who needs to hear it.

🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada’s innovation journey.

🔗 Questions, feedback, or want to connect? https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter

#BreakingInnovationParalysis #CanadianInnovation #Commercialization #HealthInnovation #Procurement #VentureCapital #HealthPolicy

Ayotola Ogunsipe is a pharmacist turned market access leader who sits at the intersection of private payers and the pharmaceutical industry. As Senior Advisor, Business Development at Express Scripts Canada, he represents insurers such as Manulife, Sun Life and Desjardins when manufacturers’ market access teams bring new therapies to Canada. He began his career as a pharmacist in Nigeria, earned a Master of Science in Pharmacology from the University of Lagos, led medical services for a major Lagos electricity utility, and co-founded a last-mile delivery company that brought prescription medications from retail pharmacies to patients. He came to Canada for his MBA at the Ivey Business School at Western University, where he was co-president of the Health Sector Club. He then worked as a RISE Fellow at Marsh McLennan and as a business consultant in Payer Solutions at TELUS Health. He is a certified Project Management Professional and Financial Modeling and Valuation Analyst, and writes regularly about market access, drug pricing and Canada’s life sciences ecosystem.

Ayotola starts behind the pharmacy counter, where patients kept leaving without their medication because of back orders. That experience still shapes how he negotiates today: “it’s one thing to get a product listed on a formulary,” he says, but patients also need to get it at the right time. He then looks at insulin and GLP-1s, two classes of medicine that grew out of Canadian science and that Canada now negotiates to buy back, and asks how the country could keep licensing, ownership and value at home.

He explains why clinical trials run in Canada matter long after the trial ends. When Canadian physicians and Canadian patients generate the data, reviewers have more confidence in it, and coverage decisions can move faster. He walks through the long road from Health Canada approval to coverage: health technology assessment by CDA or INESSS, negotiation with the pan-Canadian Pharmaceutical Alliance, and provincial listing. Together, these steps can mean a drug approved in 2026 isn’t covered until 2028.

The conversation turns to most favoured nation pricing in the US, and why some manufacturers are now launching to private plans first and delaying public negotiations. Ayotola explains how that moves risk onto private payers and employers, why he expects premiums to rise, and why he thinks drugs discovered with AI may raise costs before they lower them.

His message is that approval and access are two very different things, and Canada has to manage both.

This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.

If this shifted how you think about Canada’s innovation gap, share it with someone who needs to hear it.

🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada’s innovation journey.

🔗 Questions, feedback, or want to connect? https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter

#BreakingInnovationParalysis #CanadianInnovation #MarketAccess #DrugPricing #ClinicalTrials #PharmaPolicy #LifeSciences

Neelam Bance is a health care entrepreneur who spent most of her career in the pharmaceutical industry, in sales and marketing across diabetes, mental health, neurology and oncology at companies like Eli Lilly and Sunovion, before moving into health technology and precision medicine. She co-founded MedGeneius, a software platform that translates pharmacogenetic test results into guidance that helps clinicians choose the medications most likely to work for each patient. She is now co-founder and CEO of ODINsight Canada, which aims to securely connect Canada’s health data contributors and beneficiaries to fuel breakthroughs, accelerate innovation and drive economic growth. She is also Director of Business Development, Specialty Therapeutics, at Auxilium Health. Neelam founded the Asha Alliance, sits on the board of Yellow Brick House, and holds an MBA from the Schulich School of Business and a biology degree from the University of Toronto.

Neelam starts with what pharma taught her, and why it began to feel like “rinse and repeat”: global teams set the strategy, and Canada localized it. A sudden personal upheaval made her fearless. She asked herself what the worst that could happen really was, and for the first time in her life she took a chance on herself.

She then takes us inside pharmacogenomics, where she says 99% of people, including many physicians, don’t know what the test is. Pharma launches drugs with armies of reps and medical science liaisons. Pharmacogenomic companies have to raise awareness across every specialty with a fraction of those resources. She explains why payers look at the cost of a cheap antidepressant instead of the cost of a patient who never gets back to work, and how Ontario began funding DPYD testing only once the evidence of patients dying from a common chemotherapy drug became impossible to ignore.

The conversation turns to building a company outside the university grant system. Neelam bootstrapped while juggling three jobs, and promoted the only product she had at first: herself. Her advice to academic founders is blunt: nothing sells itself. She explains how a chance conversation at a MaRS event with a Canadian who had advised the White House led to ODINsight Canada, a consortium designed to let private health data holders, from clinic medical records to insurers and start-ups, share what their data contains without handing it over. The aim is to make Canada a place where pharmaceutical companies want to run their trials.

Her one lever for success is trust. Building it takes time, conversations and the right people in the room, which she calls “the Canadian way.”

This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.

If this shifted how you think about Canada’s innovation gap, share it with someone who needs to hear it.

🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada’s innovation journey.

🔗 Questions, feedback, or want to connect? https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter

#BreakingInnovationParalysis #CanadianInnovation #HealthData #PrecisionMedicine #Pharmacogenomics #DigitalHealth #LifeSciences #ClinicalTrials

Bob Mighell is a serial entrepreneur who has spent nearly four decades building, scaling, and exiting companies. His first, Edge Snowboards, launched in 1985 at the start of the snowboard revolution. He then spent 20 years running World Medical Equipment, which outfitted surgical suites with high-end capital equipment and made the Puget Sound Business Journal's list of fastest-growing private companies eight times. He went on to found Tilting Motor Works to commercialize his own patents on tilting three-wheeled vehicles, sold it to publicly traded Arcimoto, and set two FIM world land speed records for three-wheeled motorcycles at the Bonneville Salt Flats. After nearly three years as entrepreneur in residence at the University of Oregon's Lundquist College of Business, he did something unusual: he moved to Canada. He is now founder and CEO of Chondros Bio, a UBC spinout developing a regenerative hydrogel implant to repair cartilage and bone, and mentors startups with Creative Destruction Lab and Entrepreneurship@UBC. He holds engineering degrees from Dartmouth and an MBA from the University of Washington.

In this conversation, Bob and Natalie start with what two decades of selling into operating rooms taught him. In the US, he sold directly to the OR supervisors who held the purse strings. In Canada, buying decisions sat at the provincial level, and offering refurbished equipment at a third to half the cost of new, with an equal or better warranty, got no traction at all. He then takes us inside university tech transfer, where he estimates 80 to 85% of IP sits in a folder because no one is there to champion it. UBC did something rare: it combed its own portfolio and recruited an outside founder to commercialize a promising technology. He explains why the license is the company, why his first term sheet was a deal-breaker, and why universities move at a very different speed from business.

The conversation turns to capital and the road to market. Chondros Bio faces a seven-to-eight-year path to FDA approval, which means finding patient investors. A competitor's approval, and its roughly $330 million acquisition by Smith & Nephew, cleared both a regulatory and a reimbursement path for him. He is candid about why medtech goes south first: approval costs about the same in Canada as in the US, for a market a tenth the size. He knows three Canadian-founded companies that moved to the US for funding, one of which reincorporated in Delaware for US investors.

His one ask of Ottawa is a Canadian SBIR: true grants companies can draw on like an ATM, rather than matching or reimbursement funding that forces founders to find the money first. Without it, he warns, the US researchers Canada is now recruiting may do their science here and build their companies back home. He closes on a personal note: married to a Canadian, he's here to stay, and so is Chondros Bio for as long as he can keep it here.

This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.

If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.

🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.

🔗 Questions, feedback, or want to connect? https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter

#BreakingInnovationParalysis #CanadianInnovation #TechTransfer #MedTech #LifeSciences #SBIR #Commercialization #RegenerativeMedicine

Dr. Zayna Khayat is one of Canada's best-known health futurists. She is Chief Program Officer at AMS Healthcare, a nonprofit working toward AI-ready, compassionate health systems, and adjunct faculty and executive in residence at the University of Toronto's Rotman School of Management, where she has taught healthcare innovation since 2011. Until recently she was health futurist in residence with Deloitte Canada's healthcare and life sciences practice. Before that, she led the Health System Innovation Platform at MaRS Discovery District, served as innovation sherpa-in-chief at Radboud University Medical Center in the Netherlands, and co-founded the Dutch Ministry of Health's Health Innovation School. She co-authored Future of Aging at SE Health, began her career with a PhD in biochemistry from U of T and SickKids, and was a principal in BCG's health practice. She has keynoted from South by Southwest to the Aspen Ideas Festival.

In this conversation, Khayat and Natalie start with why she traded "innovation" for foresight. Her test is simple: unless something unlocks five times more value than the status quo, it isn't innovation. Since ChatGPT arrived in November 2022, she argues, the foresight planning window has collapsed from ten-plus years to about three. She makes the case for a new way of funding research (when everyone has the same grant writer, scoring can no longer separate the best ideas) and describes an era of AI-accelerated science in which drug discovery that once took 15 years and $3 billion may take 18 months and $10 million. New entrants like Google and OpenAI are moving in fast; she notes that OpenAI's foundation alone has a $25 billion life sciences fund, "like 12 CIHRs" from one company.

The conversation turns to risk. Khayat argues that Canada's real barrier is mindset: we are wired to spot every risk but rarely calculate the opportunity cost of not acting, and until that changes, capital alone won't fix it. She urges founders to look beyond traditional venture capital to venture philanthropy, family offices, donor-advised funds, and the largest intergenerational wealth transfer in Canadian history, and to spend a third of their time telling their story.

On sovereignty, she sees a hidden Canadian advantage. Hospital records sit largely on American EMR systems, but most other Canadian health data lives on Canadian-built platforms in primary care, home care, and long-term care. She closes with a reason for optimism: Canada's brand is at an all-time high, and startups are fielding inbound calls from partners who no longer want to do business with the US. It's a window few could have seen coming three years ago.

This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.

If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.

🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.

🔗 Questions, feedback, or want to connect? https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter

#BreakingInnovationParalysis #CanadianInnovation #HealthFutures #LifeSciences #AIinHealthcare #DrugDiscovery #HealthData #EconomicSovereignty

Daniel Perry is Director of Federal Affairs at the Council of Canadian Innovators (CCI), where he leads national advocacy on behalf of Canada's high-growth scale-up companies. Named to The Hill Times' Top 100 Lobbyists for 2026, he has testified this year before three House of Commons standing committees — Industry and Technology, Finance, and Citizenship and Immigration — each time making the same case: capital, customers, talent, and sectoral strategy aren't separate policy files, they're one connected problem. He holds a Master of Political Management from Carleton University and has written a bi-weekly political column for the Niagara-Hamilton Independent since 2021.

The conversation turns to risk. Perry shares the story of a CCI member who couldn't crack Canadian capital, flew to San Francisco, and closed a deal with an investor over drinks at the airport bar — a deal they said would have taken six to eight months at home. He is candid about the branch-plant economy, where Canadians become the worker bees while the real value flows elsewhere, and why every foreign investment should face one question: where does the IP live? When CCI loses members, he says, it's usually because a US acquirer or investor pulls the leadership team south.

On healthcare, Perry calls it a national security asset. He points to CCI's Care at Scale report, which estimates that better, more portable health data could save up to $2.4 billion a year, and warns that Canadian health data stored on foreign servers can be reached by foreign governments — making Canadian-built "maple stack" infrastructure a sovereignty issue. He closes with CCI's budget priorities: a Canadian QSBS, a startup visa, a Buy Canada policy that supports genuinely Canadian companies rather than those Canadian in name only, and a reminder, borrowed from Red Green, that we're all in this together — but duct tape won't fix it this time.

This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.

If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.

🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.

🔗 Questions, feedback, or want to connect?https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter:https://bit.ly/BIPLinkedInNewsletter

#BreakingInnovationParalysis #CanadianInnovation #InnovationEcosystem #LifeSciences #InnovationPolicy #Procurement #HealthData #EconomicSovereignty

Dr. Kean Birch holds the Ontario Research Chair in Science Policy at York University, where he has spent more than a decade studying the political economy of science, technology, and innovation. He is co-editor, with Fabian Muniesa, of Assetization: Turning Things into Assets in Technoscientific Capitalism (MIT Press), currently holds the Otto Mønsted Visiting Professorship at Copenhagen Business School, and co-edits the journal Science as Culture. His core concept, assetization, describes how things are turned into assets that someone can own, control, and extract future revenue from — a lens that reframes Canada's innovation problem as a question of ownership, not invention.

In this conversation, Dr. Birch and Natalie start at the bench, where researchers and innovators run on opposite logics: researchers pursue what isn't yet known, while innovators know where they want to go but not how to get there. People who can do both are rare, which is why ecosystems have to deliberately bring them together. He argues that early founders need accessible money to take risks, not venture capital, which only a tiny fraction of companies ever touch. He traces Canada's sell-the-resource instinct into its financial system, where public markets reward banks and miners, and explains why acquisition beats IPO for investors: acquirers pay a knowledge premium that general public-market investors won't.

The conversation turns to his sharpest diagnosis: finance has replaced innovation as the endpoint. Instead of using finance to fund innovation, the system now uses innovation to generate financial returns, and founders absorb that logic from day one, building toward an exit rather than a product, market, or company. He describes the "moments of valuation" every founder faces, from the first angel conversation to borrowing, acquisition, or IPO, each demanding a different story. On tokenization, he sees real potential to open startup investment beyond accredited investors, but only with a solid legal and regulatory foundation underneath.

On health data, Birch is blunt: an individual's data is worth pennies, but pooled, curated, and de-identified, it becomes enormously valuable. His proposal is a data wealth fund, held collectively like a natural resource fund in a public entity at arm's length from the government, with the power to improve data quality and set terms for access. He closes on what governments must do to govern assetization rather than react to it: avoid investment commitments that lock future citizens into today's decisions, and stop concentrated capital from dictating the direction of innovation itself.

This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.

If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.

🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.

🔗 Questions, feedback, or want to connect?https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter:https://bit.ly/BIPLinkedInNewsletter

#BreakingInnovationParalysis #CanadianInnovation #InnovationEcosystem #LifeSciences #Biotech #InnovationPolicy #HealthData #EconomicSovereignty

Dr. Jeffrey Crelinsten is the publisher of Research Money — Canada's leading source of intelligence on science, technology, and innovation funding — and founder of The Impact Group, an innovation-policy consultancy he started nearly 40 years ago. Research Money's readership is more than half government, plus university research leadership and the broader innovation ecosystem, and he runs its annual Ottawa conference, now heading into its 26th year. Most recently, with the Council of Canadian Innovators, he co-authored The Scale-Up Gap: From Value Creation to Value Retention, a study built on interviews with 31 founders of 30 Canadian companies that had reached real traction — customers, growth — and then sold to foreign buyers, asking them directly why.

In this conversation, Dr. Crelinsten and Natalie start where the report starts: not with failure, but with founders who'd already succeeded, then hit a wall. They needed big capital fast and executive talent who'd scaled a company before, and Canada had neither in supply. Banks won't lend against intangible IP the way they lend against real estate, and Canadian VCs, founders told him bluntly, "don't lead rounds — they follow," waiting for a foreign lead investor and ceding control to whoever showed up first. His touchstone is Doug Barber's Genome Corporation, a Hamilton microchip maker that picked a niche too small for the giants — hearing-aid chips — and took 70% of the world market, proof a Canadian company can lead a global category if it's built to.

The conversation turns to government procurement, worst of all in health: a medical device founder faces a different buyer, KPIs, and integration capacity in every hospital, and a different Ministry of Health in every province, so most give up and sell into the UK or US instead, where there's a single buyer. He traces the same failure into the university system: Canada leads the OECD in higher-education R&D spending but lags near the bottom in business R&D, because academic merit runs on peer-reviewed publications, and professors who help commercialize a student's idea are, in his account, penalized rather than rewarded — a sharp contrast to the US, where professors are paid only nine months a year and routinely take on industry contracts to cover the rest.

On where the money is, Crelinsten is blunt: Canada is awash in capital sitting in pension funds, family offices, and RSPs, mostly parked in real estate. He points to OMERS Ventures under John Ruffalo — and the board fight it took to redirect even 3% of assets into venture — and adMare BioInnovations as proof the returns are there once someone commits. He also names the politics underneath every tax debate: politicians hear "help entrepreneurs build anchor companies" as "help people get rich," which capsized the capital-gains tax fight and keeps a siloed bureaucracy from acting on what its own frontline staff already know. He closes with a moonshot: federal, provincial, and municipal leaders publicly committing, Kennedy-style, to build five Canadian anchor companies in one sector — health and life sciences, since fixing that also fixes the healthcare system.

This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.

If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.

🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.

🔗 Questions, feedback, or want to connect? https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter: https://bit.ly/BIPLinkedInNewsletter
#BreakingInnovationParalysis #CanadianInnovation #InnovationEcosystem #LifeSciences #Biotech #Pharma #InnovationPolicy #EconomicSovereignty

Dr. Kostas Trakas is a pharma builder and former Johnson & Johnson executive, and co-founder of Exsilios Pharma — a Canadian specialty pharmaceutical company that sources FDA, EMA, and MHRA-approved late-stage assets and secures Canadian commercialization rights across rare disease, oncology, immunology, CNS, and cardiometabolic indications. He holds a PhD and a Master's in pharmacology from the University of Toronto, and spent over a decade at J&J in global marketing and market access leadership, including building companion diagnostic policy platforms and public-private partnership models across EMEA and LatAm. Before Exsilios, he led Exactis Innovation, taking Canada's largest oncology real-world evidence network from a grant-funded model toward commercial self-sufficiency. He writes and speaks publicly on where Canada's Life Sciences Task Force has fallen short, and is currently pivoting Exsilios toward developing early-stage Canadian IP into a genuine anchor company.

In this conversation, Dr. Trakas and Natalie trace the entire pipeline from the ground up. It starts with the argument that Canada's most underused strategic asset isn't a new discovery at all — it's the tokenized, longitudinally-linked health data sitting inside a single-payer system, an asset the fragmented, privately-insured US system structurally can't replicate, and one Canada still won't let researchers actually access. From there it moves into funding: Dr. Trakas's own experience inheriting ten years of grant-funded operations and being told to make them commercially self-sufficient, his blunt dismissal of Canada's incubator and accelerator model as "checkbox" theatre, and the pension fund paradox where the Maple Eight are structurally barred by their own fiduciary rules from investing in the small domestic companies that need them most — a policy Canada wrote into its own regulations roughly twenty years ago and has never revisited.

The conversation turns next to why Canadian founders default to selling rather than building — Dr. Trakas's own theory that Canadians settle for being what he calls the "second banana," happy to sell at the first good offer rather than aspiring to build the next Shopify — and what it would actually take to produce Canada's first true anchor companies and the biotech clusters that follow them. From there they dismantle the reimbursement gauntlet directly: Dr. Trakas's case for collapsing the PMPRB, CDA-AMC, and pCPA into a single agency instead of three sequential closed-door negotiations that can take a product two years to reach a single provincial formulary, set against the reality that Canadians access only about 18% of globally available medicines versus an OECD average of 28%. The episode closes on the geopolitical stakes: China's decade-long playbook of steel, then EVs, now life sciences, and why Dr. Trakas believes Canada can run the same playbook rather than keep funding runway for other countries to take off.

This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.

If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.

🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.

🔗 Questions, feedback, or want to connect?https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter:https://bit.ly/BIPLinkedInNewsletter

#BreakingInnovationParalysis #CanadianInnovation #InnovationEcosystem #LifeSciences #Biotech #Pharma #InnovationPolicy #EconomicSovereignty

Dr. Anu Rebbapragada has spent over two decades translating diagnostic innovation into clinically trusted, commercially viable services — as a clinical microbiologist and high-complexity lab director, a national leader across Canadian diagnostic lab networks, a MedTech executive at a Fortune 500 global diagnostics company, and a strategic advisor to entrepreneurial ventures. She holds a PhD in microbiology and molecular genetics, has published over 40 peer-reviewed papers, sits on Canada's first national AI-in-clinical-decision-support standards committee (CAN/DGSI 138), and completed Harvard Medical School's executive program on AI implementation in healthcare.

In this conversation, Anu walks through what she calls "pilot purgatory" — the graveyard where excellent Canadian diagnostic research dies before it ever reaches routine practice. She unpacks why the problem isn't the science: it's a fragmented, thirteen-jurisdiction reimbursement patchwork where the identical test on the identical platform pays out differently province to province, a regulatory pathway with no equivalent to the U.S. lab-developed-test route, and what she terms "institutional inertia" — staff so stretched sustaining outdated, paper-based workflows that they have neither the bandwidth nor the incentive to adopt something new. She traces one case in detail: a McMaster-spun-out molecular test for endometriosis, clinically promising, structurally boxed in by the very system meant to bring it to patients.

The conversation turns to what Anu calls a kind of collective amnesia: Canada proved during COVID that rapid, responsible diagnostic innovation at scale is possible — home collection, point-of-care testing, virtual portals, all stood up fast and safely — only to revert to sluggish, pre-pandemic defaults once the pressure lifted. She and Natalie dig into the binary nature of Canadian healthcare (public system or private workaround, with little in between), the "postal code lottery" of provincial fragmentation, and why she believes the missing ingredient isn't more pilots or more publications but public awareness and grassroots advocacy — health consumers demanding better tests exist, rather than assuming the status quo is the ceiling.

This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.

If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.

🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.

🔗 Questions, feedback, or want to connect?https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter:https://bit.ly/BIPLinkedInNewsletter

#BreakingInnovationParalysis #CanadianInnovation #InnovationEcosystem #Diagnostics #HealthTech #InnovationPolicy #HealthcareReform

Dr. Andrew Maxwell has spent three decades studying how people inside institutions actually make innovation decisions, from his early years at ABB through a PhD examining investor judgment to his current role as a professor of technology and entrepreneurship at York University's Lassonde School of Engineering. He's the founder of the BEST program, author of the Innovation Doctor series on Substack, and runs Avatar Innovations, working across academic health centres, federal research funders, and the incubator ecosystem meant to carry ideas from lab to market.

In this conversation, Andrew walks through why culture sits underneath everything else in his five-driver framework — culture, capability, incentives, institutions, and technology — and why so many of Canada's innovation failures get mislabelled as technical problems when they're actually cultural ones: assumptions nobody wants to challenge, and a default tendency to keep doing what we did yesterday. He calls this his "laws of innovation inertia," a direct parallel to Newton's laws — bodies at rest stay at rest unless something forces them to move.

We get into why research funders like NSERC and CIHR were never mandated to produce productivity or adoption outcomes in the first place, only publications and advancing knowledge, and why that mismatch quietly shapes what gets built and what gets shelved. Andrew built TechConnect at York specifically to close that gap, training researchers to ask what a user actually needs rather than just optimizing a technical spec. He also makes the case that the skillset required to discover something and the skillset required to persuade someone to adopt it are fundamentally different, and that most incubators aren't structured to bridge that particular chasm.

The conversation turns to funding itself: Andrew's contrarian take that venture capital's milestone-based, real-options structure is actually more disciplined than government research funding, which hands out money with far less accountability. He introduces the idea of a "farm team," regions and companies that quietly accept talent will outgrow them and leave, and Natalie pushes back with the question underneath it all: is Canada a farm team, or does it not know what it is yet. Andrew is candid that he doesn't have a clean answer, and that may be part of the problem.

This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.

If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.

🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.

🔗 Questions, feedback, or want to connect?https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter:https://bit.ly/BIPLinkedInNewsletter

#BreakingInnovationParalysis #CanadianInnovation #InnovationEcosystem #YorkUniversity #InnovationPolicy #TechTransfer

David Carter has spent 13 years as CEO of Innovation Factory, Hamilton's regional innovation centre, helping founders in tech, digital health, and advanced manufacturing bring their ideas to market. Before that, he built and scaled his own software company and worked as a CTO, experience that still shapes how he thinks about product growth and what it actually takes to scale. He's also a co-founder of the Synapse Life Science Consortium, linking Hamilton's life sciences ecosystem across McMaster, Hamilton Health Sciences, and St. Joseph's Healthcare, and sits on boards spanning digital health and national innovation networks.In this conversation, David walks through the tangle of institutions a Canadian founder has to navigate between lab bench and fundable company, and why that tangle matters less than people assume. There's real overlap between industry liaison offices like McMaster's Milo, campus-led accelerators like the Forge, and regional innovation centres like his own, but David makes the case that it's survivable: "there's no wrong door," and founders get routed to the right resource no matter where they walk in first.We get into how research gets stuck, not because Canadian researchers lack fundable ideas, but because many simply don't know what to do with them or where to take them, leaving genuinely brilliant work shelved once a PhD wraps and the researcher moves on. David explains the handoff chain from university tech-transfer offices to campus incubators to regional innovation centres, and why nobody at any stage is trying to "hog the glory" from the startups themselves.David also raises a question Canada still can't answer: once public money goes into a company, does anyone track what happened to it? He makes the case for real accountability tied to non-dilutive funding, not to punish failure, but to actually learn from it, and admits candidly that even he doesn't know whether early government support was the thing that got a company like Shopify through a bad day, or just something everyone piles credit onto after the fact. He's optimistic all the same: a new generation of founders who grew up with the internet, paired with the disruptive force of AI, feels to him like another point of inflection, the kind he last saw in the mid-90s.This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.🔗 Questions, feedback, or want to connect? https://augmentios.com/contact📩 Subscribe to my LinkedIn Newsletter: ⁠https://bit.ly/BIPLinkedInNewsletter#BreakingInnovationParalysis #CanadianInnovation #InnovationEcosystem #Hamilton #McMasterUniversity #StartupCanada #TechTransfer

Walter Robinson is a bilingual public affairs executive with 30 years of policy, legislative, and regulatory experience at every level of Canadian government — from federal director of the Canadian Taxpayers Federation, where his testimony helped shape the Romanow Commission, to Chief of Staff at Ottawa City Hall, to VP roles at Innovative Medicines Canada and senior pharma leadership at Purdue. Alongside that, he's built a parallel career in rare disease and cancer advocacy: founding board member of SecondStreet.org, former board member of the Ottawa Hospital, past chair of the Ottawa Cancer Foundation, and advisory committee member with the Lundin Cancer Fund's Glioblastoma Research Program. Based in Montreal, Walter now runs his own AI and healthcare consultancy.

In this conversation, Walter walks through why Canada builds world-class upstream research — strongest recent example, a $443-million national AI strategy that funded three institutes and over 100 research chairs — and still can't get that work across the finish line into commercialized, Canadian-owned companies.

We get into why he sees the gap as structural rather than cultural: constitutional divisions between federal and provincial jurisdiction, an academic system built on publish-or-perish rather than commercialize-or-perish, and the absence of anything like the U.S. Bay-Dole Act, which gave American universities one consistent national rulebook for moving IP out of the lab in 1980. Canada, he argues, never built that predictability, and the result is a patchwork of hybrid ownership models and career bureaucrats running tech transfer offices instead of people with venture backgrounds.

Walter also gives a postmortem on Bills C-27 and C-72, both of which died on the order paper, and explains how the Carney government is resequencing that same legislative ground through Bill S-5 — sending it to the Senate first to get around federal-provincial jurisdictional fights by framing health data as economic union, not health policy. He's cautiously optimistic about the sequencing, with one caveat: government funding bodies still run on 12-to-18-month cycles while AI capability is moving weekly, and he warns that some of today's AI health investments could become "the next round of corporate welfare headlines" in five years if there's no accountability built in.

We also dig into Canada's slipping share of global clinical trials — down from 6% to 4% in five years, roughly $2.5 billion and 20,000 jobs — and why the country is strong at Phase 1 and 2 trials but stalls at Phase 3 and 4, exactly the stages where AI-driven recruitment, retention, and pharmacovigilance could help close the gap. Walter closes with a personal note: as a patient across three generations of clinical research himself, he makes the case that treating life sciences as a matter of national sovereignty isn't abstract policy — it's how Canada gets on the winning team.

This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.

If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.

🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.

🔗 Questions, feedback, or want to connect?https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter:https://bit.ly/BIPLinkedInNewsletter

#BreakingInnovationParalysis #CanadianInnovation #HealthSovereignty #LifeSciences #ClinicalTrials #PublicPolicy #TechTransfer

Marc-Antoine Benglia has spent three decades studying why some innovation ecosystems outperform others, starting with graduate research in 1993 comparing Silicon Valley, Cambridge, and Sophia Antipolis using an expanded version of Porter's Diamond framework. He's since built and sold two companies out of Ottawa, Hemera (acquired by Jupiter Media) and Axentra Corporation, whose spinoff Kwilt was acquired by Western Digital. He now leads Innovacité, La Cité's applied research and innovation centre in Ottawa.In this conversation, Marc-Antoine traces what actually made Silicon Valley outpace every other tech hub he studied: not just capital, but demand (early army contracts), a culture of entrepreneurship the rest of the world doesn't share, and a full supporting ecosystem of lawyers, accountants, and suppliers who understand how to build and finance a startup. He contrasts that with France's more centralized, government-and-big-company-driven model, and Cambridge's hybrid of the two.He then walks through his own founding story: building Hemera in the late '90s inside a genuinely well-organized Quebec funding pipeline (government-backed personal loans, then FTQ, then Caisse de Dépôt, then SGF, each organization handing off the entrepreneur to the next stage) and discovering, a decade later with Axentra, that this staged infrastructure no longer existed anywhere in Canada. Unable to find a Canadian VC willing to lead a round, he had to raise from Deutsche Telekom's Silicon Valley arm instead. When Axentra spun off Kwilt, he rented an office in California and spent two weeks a month there just to make the company look local enough to sell. One of his own investors later told him he'd have closed the deal five times faster if he'd actually moved the business there permanently, a decision he now considers his biggest mistake.From his time working inside Western Digital after the Kwilt acquisition, he shares what he'd tell his younger founder self about learning innovation from inside a major corporation, and why he now advises young entrepreneurs to seek out headquarters roles at big players like Google, not a Canadian subsidiary, before starting their own company, because investors read that pedigree as instant credibility.We also get into why Canadian universities retaining IP quietly kills spinouts before they start, why he's fighting a losing battle paying top AI and biotech researchers a fraction of what Google or comparable US employers offer under union-constrained pay scales, and what China's deliberate, committed strategy on electric vehicle batteries reveals about the cost of Canada's inertia, using the North Vault battery plant delays and Canada's decade-long refinery permitting timelines as concrete examples of the same paralysis playing out in energy and manufacturing, not just tech.The conversation closes on the resource analogy running through the whole discussion: Canada sells its raw materials, its ideas, its PhDs, and its people cheap, then buys the finished product back at several times the price, whether that's a car, a cure, or a company.This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.🔗 Questions, feedback, or want to connect? https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter: ⁠https://bit.ly/BIPLinkedInNewsletter#BreakingInnovationParalysis #CanadianInnovation #Entrepreneurship #LifeSciences #TechEcosystem #SiliconValley

Dr. Gerry Wright has spent 33 years at McMaster University, and this year his lab had an extraordinary run: four new antibiotic candidates, including lariocidin, a discovery published in Nature that targets a vulnerability no antibiotic on the market currently exploits. He's also spent two decades on the other side of the table, reviewing grants for the Canadian Institutes of Health Research (CIHR), and he's lived the commercialization gap firsthand, having founded and lost a company built on a single compound.In this conversation, Gerry walks through why discovery, the part Canada is genuinely excellent at, is the easy part, and why turning a Nature-published finding into an actual drug is close to impossible here. Getting a drug to market costs north of a billion dollars; Canada's entire federal health research budget doesn't come close. There's substantial funding for discovery, and essentially none for development, so promising science stalls at exactly the point where other countries start investing seriously.We get into how CIHR's own grant review process works from the inside: panels evaluating roughly 50 proposals at a time, funding success rates now hovering near 10%, down from 20-25% two decades ago, and why that scarcity quietly pushes reviewers toward safe, incremental proposals over genuinely novel ones, even when nobody intends it that way. Gerry explains why a well-intentioned new program meant to fund riskier science ended up building an entirely separate bureaucracy instead of reinforcing the systems that already work, and why the loss of five-year renewable funding matters more than it sounds, since it's what lets a lab actually retain skilled staff long-term.He makes the case for something Canada doesn't have: a version of the U.S. NIH's SBIR program, competitive, non-dilutive funding specifically for companies, not academics, that has underwritten a large share of American drug, vaccine, and diagnostics development for decades. We talk about why Canadian pension funds and banks stay parked in resource industries while U.S. capital treats biotech risk the way it treats a bet in Vegas, and why antibiotics specifically are one of the hardest sells in the entire pharmaceutical industry: curing a disease outright is, perversely, worse business than managing a chronic one.Gerry also talks candidly about what happened to his first company, built around a single compound discovered in his lab and published on the cover of Nature, that no Canadian investor would fund. It became a Delaware-incorporated company backed by NIH resources and Boston investors, and ultimately failed when an unexpected liability turned up late in development, the same risk every drug faces, just absorbed entirely by people outside Canada. He explains what he's doing differently this time: keeping the assets in Canada, diversifying beyond a single compound and beyond antibiotics into cancer targets, and raising non-dilutive funding from the UK and EU because that kind of support still doesn't exist domestically.Along the way: the insulin callback that keeps surfacing in this series (we don't manufacture it here anymore either), a former PhD student who had to launch his antibiotic-resistance-monitoring company out of New York because Canadian hospitals don't have the competitive incentive structure to pay for it, and Gerry's blunt read on the country's research culture: we don't lack brains, we don't lack ambition, we just export both.🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.🔗 Questions, feedback, or want to connect? https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter: ⁠https://bit.ly/BIPLinkedInNewsletter#BreakingInnovationParalysis #CanadianInnovation #DrugDiscovery #LifeSciences #AntimicrobialResistance #McMasterUniversity

Amos Adler has spent nearly two decades as founder and CEO of MEMOTEXT Corp, a digital patient engagement platform built to drive medication adherence through personalized, evidence-based messaging. He later co-founded A4i, a joint venture with CAMH supporting people living with schizophrenia through digital engagement, and is now building MTXT.ai, aimed at compressing the years-long gap between a validated research idea and an actual deployable health product.In this conversation, Amos traces how MEMOTEXT evolved from a single content-delivery engine, what would later be called a just-in-time adaptive intervention, into the toolkit behind dozens of patient engagement applications, and why he treats every accelerator, grant, and partnership as a long-term play rather than a quick win: in his world, next week is effectively five years away, and validation takes years no matter how good the idea is.We get into a genuinely counterintuitive finding from his own experience: Canadian IP terms for academic principal investigators are actually more favorable than American ones, yet Canadian founders still struggle to execute at the same speed, largely because the U.S. runs the equivalent of twenty separate CIHRs to Canada's one, with a customer base to match. Amos is blunt about where Canadian incubators and accelerators fall short: too many are staffed by people who've never built anything themselves, too many measure success by dollars raised rather than revenue or customer traction, and too few are willing to cut a startup loose when it isn't working. He contrasts that with Creative Destruction Labs' model, where if no mentor raises their hand for you, you're out, and argues that exact kind of accountability, letting bad ideas die instead of keeping them on life support indefinitely, is what's missing from Canadian innovation culture. The result, in his words, is a landscape full of zombie companies: neither funded enough to scale nor allowed to fail.He's equally direct about founders themselves. Many of the academic entrepreneurs he's worked with, including people literally curing cancer, have never been taught the basics of selling, and treat business development as beneath the science, when it's the only thing that actually gets an idea to a patient. Revenue, in his view, solves problems no amount of grant writing ever will.The conversation closes on the familiar resource pattern this show keeps circling back to, extended into new territory: Canada exports its raw materials, its ideas, its IP, its highly subsidized and highly educated people, then buys the finished product back at a markup, whether that's a car, a can of aluminum we already produced, or a drug developed here and commercialized somewhere else. Amos offers one genuine point of optimism: researchers displaced by recent U.S. funding cuts are starting to land in Canada, and he argues that's exactly the kind of investment Canada should be scaling aggressively, if the country can find the will to plan ten and twenty years out instead of defaulting to consensus and stability.This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.🔗 Questions, feedback, or want to connect? https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter: ⁠https://bit.ly/BIPLinkedInNewsletter#BreakingInnovationParalysis #CanadianInnovation #DigitalHealth #HealthTech #Entrepreneurship #MentalHealth

Dr. Nadine Tatton is a University of Toronto-trained neuroscientist who has spent her career at the intersection of neurodegenerative disease research and drug development. She helped grow the Association for Frontotemporal Degeneration's research funding from $250,000 to $6 million, plus another $10 million in partnered programs, later supported strategy at Alector, and most recently served as executive director of the Critical Path for Alzheimer's Disease Consortium. She left Canada nearly two decades ago to build that career in the US, and she's watching from the outside for a way back in.Nadine opens with a theory none of this show's earlier guests have raised: that Canadian risk aversion isn't just a funding problem, it's a cultural inheritance from Victorian Britain, where boasting about achievement was considered ungentlemanly, and where "amateur" outranked "professional" as the higher compliment. She traces a straight line from that 19th-century mindset to a very current Canadian instinct to celebrate coming in second, and argues that instinct, more than any single policy, shapes everything downstream: what gets funded, what gets said out loud, and who eventually leaves.She and Natalie trace how that plays out concretely: identical tech roles paying tens of thousands of dollars less in Canada than the equivalent US position once stock, bonuses, and total compensation are factored in, Canadian startups typically taking years longer than their US counterparts to reach the same funding stage, and founders describing having to navigate six to eight different taxes just to get a company off the ground, only to be taxed again on any profit they manage to generate. Nadine also walks through why so many Canadian-founded companies incorporate in Delaware rather than at home: it's simply easier, and it's advice tech transfer offices themselves routinely give.Drawing on her years building a nonprofit research funding engine in the US, including a single $40 million donation that permanently secured an organization's future, Nadine contrasts the scale and business sophistication of American disease-advocacy fundraising with what's realistically achievable in Canada, and revisits the Connaught Labs story: 65 years spent developing and manufacturing insulin and diphtheria treatments domestically, sold off in stages through the '70s and '80s, and a capability Canada has never rebuilt since.The conversation closes on two notes of genuine optimism: Nadine sees the current disruption in US research funding as an opening for Canada to attract displaced scientific talent, and she argues Canada has leaned on a single trading partner for too long when it has the global trust and reputation to diversify into much broader partnerships. And when asked directly what role she'd want if she returned, her answer is blunt: not inside government. She wants the freedom to say what she actually thinks.This is Breaking Innovation Paralysis: research for a book on why Canada keeps losing the cures, capital, and companies it builds. Not a promotional platform, an honest look at the structural gaps: inertia, risk aversion, and diffusion of responsibility.If this shifted how you think about Canada's innovation gap, share it with someone who needs to hear it.🎧 New episodes weekly. Subscribe for more honest conversations with the people building, gatekeeping, and navigating Canada's innovation journey.🔗 Questions, feedback, or want to connect? https://augmentios.com/contact

📩 Subscribe to my LinkedIn Newsletter: ⁠https://bit.ly/BIPLinkedInNewsletter#BreakingInnovationParalysis #CanadianInnovation #Neuroscience #DrugDevelopment #BrainDrain #LifeSciences

Welcome to the premiere episode of Breaking Innovation Paralysis, where we dive into the urgent need for change within Canada's health innovation ecosystem.

A Bold Vision for Canada

Natalie Yeadon opens the series with a powerful proposal from Dr. Kevin Smith, president and CEO of Toronto's University Health Network. He envisions Canada as the top destination for taking scientific discoveries to market. Yet, as Yeadon points out, Canada has a troubling history of failing to capitalize on its own innovations, citing the sad irony that while we take pride in discovering insulin, we import almost all of it today.

"We sell the cheap ingredients... to foreign companies, and then we spend billions of dollars buying back the finished cake."— Natalie Yeadon

This cycle highlights a deeper issue: Canada doesn't have an innovation deficit; it suffers from an institutional courage gap. Yeadon reflects on her experiences in clinical settings and the pharmaceutical industry, emphasizing that the real challenge lies in overcoming the fear of taking risks within our systems.

The Three Biases of Innovation Paralysis

Yeadon identifies three behavioral biases that contribute to this paralysis:

• Inertia: The tendency to stick to familiar methods, often at the expense of better, more efficient solutions.
• Diffusion of Responsibility: A fragmented system where accountability is unclear, leading to inaction.
• Bidirectional Risk Aversion: A culture that prioritizes avoiding blame over fostering innovation.

These biases create a climate where innovation struggles to thrive, and as Yeadon argues, we must confront them head-on to foster a more dynamic healthcare environment.

A Call to Action

Yeadon's company, Augmentios, is conducting a comprehensive audit of Canada's health innovation pipeline, examining everything from university labs to patient care. The goal is to dismantle the psychological barriers that stifle innovation and implement actionable strategies to create a more effective healthcare system.

"We're here to conduct a systematic, room-by-room audit of the entire Canadian health innovation pipeline."— Natalie Yeadon

Through tools like pre-mortems, decision journaling, and safe-to-fail simulations, Augmentios seeks to empower healthcare leaders and innovators to embrace risk and creativity.

Join the Movement

As we continue to explore these critical themes throughout the season, we invite you to reflect on your own experiences within the healthcare system. If you have insights or stories to share, connect with us. Together, we can cultivate the institutional courage necessary to unlock Canada's full potential in health innovation.

For more insights, visit Augmentios.com and stay tuned for upcoming episodes!